RSI spoločnosti Kazia Therapeutics
Aká je hodnota metriky RSI spoločnosti Kazia Therapeutics?
Hodnota metriky RSI spoločnosti Kazia Therapeutics Limited je 43.35
Aká je definícia metriky RSI?
Index relatívnej sily (Relative strength index - RSI 14) je technický ukazovateľ, ktorý sa radí medzi momentum indikátory a meria rýchlosť a zmenu ceny. Jeho hodnota sa pohybuje medzi 0 a 100 a používa sa na charakterizovanie prekupovaného a prepredaného stavu.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Kazia Therapeutics
Čomu sa venuje spoločnosť Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Firmy s metrikou rsi podobnou spoločnosti Kazia Therapeutics
- Hodnota metriky RSI spoločnosti Hindustan Fluorocarbons je 43.34
- Hodnota metriky RSI spoločnosti Chatham Lodging Trust je 43.34
- Hodnota metriky RSI spoločnosti A2Z Technologies Canada je 43.34
- Hodnota metriky RSI spoločnosti Copa S.A je 43.34
- Hodnota metriky RSI spoločnosti Pershing Square je 43.34
- Hodnota metriky RSI spoločnosti Shivam Autotech je 43.34
- Hodnota metriky RSI spoločnosti Kazia Therapeutics je 43.35
- Hodnota metriky RSI spoločnosti A10 Networks Inc je 43.36
- Hodnota metriky RSI spoločnosti Cnova N.V je 43.36
- Hodnota metriky RSI spoločnosti Network18 Media & Investments je 43.36
- Hodnota metriky RSI spoločnosti COMPASS Pathways plc je 43.36
- Hodnota metriky RSI spoločnosti FG New America Acquisition je 43.36
- Hodnota metriky RSI spoločnosti Natwest Gr.Plc Ls 1,0769 je 43.36